Julphar to inject SAR 300M in pharma, biotech facility in Saudi Arabia

Gulf Pharmaceutical Industries (Julphar) unveiled plans to invest nearly SAR 300 million (AED 293 million) over the few coming years to build a state-of-art pharma and biotech manufacturing facility in Saudi Arabia.

The green field project will include complex biologics, sterile and general formulation drug manufacturing and will follow the highest quality standards, fulfilling SFDA, EMA, and USFDA guidelines.

Julphar will introduce a range of complex biologics and other medications after the completion of the facility.

The project complements Julphar’s continued investment initiatives in advanced manufacturing capabilities at the company’s main manufacturing campus in Ras Al Khaimah in UAE.

The project implementation is planned to be initiated in Q1 2025, in line with the company’s growth strategy in the key markets in the GCC.